Weight loss capsule
Total raised: $59M
Valuation: $200M
Investors 2
| Date | Name | Website |
| - | XT Hi-Tech | xthitech.c... |
| - | Agate Medi... | agate-inve... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.12.2021 | IPO | $51M | - |
| 09.04.2019 | - | $8M | - |
Mentions in press and media 5
| Date | Title | Description |
| 18.09.2024 | Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device | Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. CAESAREA, Israel, Sept.... |
| 07.03.2024 | Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance | CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- Epitomee® (TASE: EPIT) announced today that on February 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in the USA, reaching a significant milestone in the company's journ... |
| 16.01.2024 | Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule | CAESAREA, Israel, Jan. 16, 2024 /PRNewswire/ -- Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety a... |
| 14.12.2021 | Epitomee Medical announced the completion of $51 million IPO on the Tel Aviv Stock Exchange; The offering was made at a pre-money valuation of $200 million | TEL AVIV, Israel, Dec. 14, 2021 /PRNewswire/ -- Epitomee Medical (TASE: EPIT), the Israel-based bio-medical company, announced this morning the completion of its Initial Public Offering on the Tel Aviv Stock Exchange: The company raised $51... |
| 09.04.2019 | Epitomee Closed $8M Equity Financing Round | Epitomee Medical, a Caesarea, Israel-based bio-medical company developing treatments for the overweight and obese population, including treatment of glycemic control, weight reduction, and hypertension based on its swallowable-device gastri... |